$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

$xers Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000186709623000031 Filed on March 08, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$33.20M	$33.14M	$110.2M
YoY Change	50.39%	54.67%	122.32%
Cost Of Revenue	$5.319M	$6.291M	$22.63M
YoY Change	-15.21%	28.68%	69.95%
Gross Profit	$27.88M	$26.85M	$87.61M
YoY Change	76.44%	62.35%	141.55%
Gross Profit Margin	83.98%	81.02%	79.47%
Selling, General & Admin	$33.61M	$34.36M	$137.7M
YoY Change	-6.43%	-33.9%	9.57%
% of Gross Profit	120.55%	127.94%	157.22%
Research & Development	$4.838M	$4.955M	$20.97M
YoY Change	-22.59%	-50.85%	-16.67%
% of Gross Profit	17.35%	18.45%	23.93%
Depreciation & Amortization	$364.0K	$3.077M	$1.399M
YoY Change	13.4%	242.27%	5.27%
% of Gross Profit	1.31%	11.46%	1.6%
Operating Expenses	$38.44M	$42.02M	$158.7M
YoY Change	-8.82%	-32.88%	5.19%
Operating Profit	-$13.28M	-$15.17M	-$81.94M
YoY Change	-54.33%	-67.07%	-28.84%
Interest Expense	$6.200M	-$2.524M	$15.30M
YoY Change	77.14%	46.23%	112.5%
% of Operating Profit
Other Income/Expense, Net	-$3.557M	$4.426M	-$14.14M
YoY Change	-29.54%	-658.13%	86.87%
Pretax Income	-$16.83M	-$13.27M	-$96.08M
YoY Change	-50.67%	-73.88%	-21.71%
Income Tax	$0.00	-$338.0K	-$1.424M
% Of Pretax Income
Net Earnings	-$16.83M	-$12.93M	-$94.66M
YoY Change	-50.07%	-74.54%	-22.87%
Net Earnings / Revenue	-50.71%	-39.01%	-85.86%
Basic Earnings Per Share	-$0.12		-$0.70
Diluted Earnings Per Share	-$0.12	-$0.10	-$0.70
COMMON SHARES
Basic Shares Outstanding	137.3M shares	136.0M shares	135.6M shares
Diluted Shares Outstanding	137.1M shares		135.6M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.10M	$122.0M	$122.0M
YoY Change	-28.03%	19.07%	19.07%
Cash & Equivalents	$50.98M	$122.0M	$122.0M
Short-Term Investments	$44.12M	$0.00	$0.00
Other Short-Term Assets	$10.51M	$9.287M	$9.287M
YoY Change	104.24%	102.38%	102.38%
Inventory	$29.04M	$24.74M	$24.74M
Prepaid Expenses	$10.51M	$9.287M
Receivables	$30.86M	$30.83M	$30.83M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$165.5M	$186.8M	$186.8M
YoY Change	-6.78%	31.01%	31.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.477M	$5.516M	$9.508M
YoY Change	2.96%	-16.76%	43.47%
Goodwill	$22.86M	$22.86M
YoY Change	0.0%	0.0%
Intangibles	$117.9M	$120.6M
YoY Change	-8.42%	-8.25%
Long-Term Investments
YoY Change
Other Assets	$4.729M	$4.730M	$4.730M
YoY Change	116.53%	470.57%	470.57%
Total Long-Term Assets	$155.8M	$157.7M	$157.7M
YoY Change	-2.64%	-2.51%	-2.51%
TOTAL ASSETS
Total Short-Term Assets	$165.5M	$186.8M	$186.8M
Total Long-Term Assets	$155.8M	$157.7M	$157.7M
Total Assets	$321.4M	$344.5M	$344.5M
YoY Change	-4.82%	13.2%	13.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.98M	$4.606M	$4.606M
YoY Change	8.04%	-48.39%	-48.39%
Accrued Expenses	$20.15M	$36.79M	$66.36M
YoY Change	-41.36%	-25.06%	-2.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$81.42M	$73.62M	$73.62M
YoY Change	22.46%	-6.86%	-6.86%
LONG-TERM LIABILITIES
Long-Term Debt	$187.6M	$187.1M	$187.1M
YoY Change	36.32%	112.42%	112.42%
Other Long-Term Liabilities	$31.00K	$31.00K	$35.12M
YoY Change	-85.51%	-98.15%	-5.29%
Total Long-Term Liabilities	$31.00K	$31.00K	$222.2M
YoY Change	-85.51%	-98.15%	77.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.42M	$73.62M	$73.62M
Total Long-Term Liabilities	$31.00K	$31.00K	$222.2M
Total Liabilities	$291.3M	$299.3M	$299.3M
YoY Change	20.79%	43.13%	43.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$571.6M	-$554.8M
YoY Change	15.76%	20.58%
Common Stock	$14.00K	$14.00K
YoY Change	0.0%	7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.05M	$45.19M	$45.19M
YoY Change
Total Liabilities & Shareholders Equity	$321.4M	$344.5M	$344.5M
YoY Change	-4.82%	13.2%	13.2%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$16.83M	-$12.93M	-$94.66M
YoY Change	-50.07%	-74.54%	-22.87%
Depreciation, Depletion And Amortization	$364.0K	$3.077M	$1.399M
YoY Change	13.4%	242.27%	5.27%
Cash From Operating Activities	-$26.14M	-$16.12M	-$102.9M
YoY Change	-46.0%	-44.31%	7.7%
INVESTING ACTIVITIES
Capital Expenditures	$238.0K	$132.0K	$524.0K
YoY Change		-200.76%	-51.71%
Acquisitions
YoY Change
Other Investing Activities	-$43.74M	$9.300M	$34.99M
YoY Change	-751.3%	-74.68%	-64.68%
Cash From Investing Activities	-$43.98M	$9.168M	$34.46M
YoY Change	-754.84%	-74.95%	-64.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$30.00M
YoY Change			11.11%
Debt Paid & Issued, Net	$0.00		$43.50M
YoY Change	-100.0%
Cash From Financing Activities	-$863.0K	49.16M	$127.5M
YoY Change	-101.1%	39224.8%	367.84%
NET CHANGE
Cash From Operating Activities	-$26.14M	-16.12M	-$102.9M
Cash From Investing Activities	-$43.98M	9.168M	$34.46M
Cash From Financing Activities	-$863.0K	49.16M	$127.5M
Net Change In Cash	-$70.98M	42.21M	$59.04M
YoY Change	-294.47%	442.41%	98.96%
FREE CASH FLOW
Cash From Operating Activities	-$26.14M	-$16.12M	-$102.9M
Capital Expenditures	$238.0K	$132.0K	$524.0K
Free Cash Flow	-$26.38M	-$16.25M	-$103.4M
YoY Change		-43.6%	7.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001867096
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40880
CY2022	dei	Entity Registrant Name EntityRegistrantName	XERIS BIOPHARMA HOLDINGS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-1082097
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	180 N. LaSalle Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60601
CY2022	dei	City Area Code CityAreaCode	844
CY2022	dei	Local Phone Number LocalPhoneNumber	445-5704
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	XERS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	209300000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	137288602	shares
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Chicago, Illinois
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121966000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67271000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35162000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30830000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17456000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24735000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9287000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4589000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	186818000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	142596000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5516000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3992000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22859000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	22859000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120607000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131450000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4730000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	829000	usd
CY2022Q4	us-gaap	Assets Assets	344522000	usd
CY2021Q4	us-gaap	Assets Assets	304361000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4606000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8924000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1580000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36786000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	usd
CY2022Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	16818000	usd
CY2021Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	15041000	usd
CY2022Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	11173000	usd
CY2021Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	4000000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2658000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1987000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73621000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79040000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	187075000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9402000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	25688000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22531000	usd
CY2022Q4	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	0	usd
CY2021Q4	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	5991000	usd
CY2022Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6883000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3518000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4942000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	31000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1676000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	299335000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	209130000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136273090	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136273090	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124873316	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124873316	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	599966000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	555359000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-554770000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-460110000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	45187000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	344522000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304361000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	110248000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49590000	usd
CY2022	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	22634000	usd
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	13318000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20966000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25160000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	137745000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	125718000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10843000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	550000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	192188000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	164746000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-81940000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-115156000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	2578000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	313000	usd
CY2022	us-gaap	Interest Expense InterestExpense	15325000	usd
CY2021	us-gaap	Interest Expense InterestExpense	7180000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1760000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	702000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3157000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14144000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7569000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-96084000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-122725000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1424000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94660000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	7000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-38000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94652000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122762000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.55
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.55
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135628721	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135628721	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79027062	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79027062	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33761000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26925000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	137655000	usd
CY2021	xers	Adjustments To Additional Paid In Capital Equity Issued For Transactions AdjustmentsToAdditionalPaidInCapitalEquityIssuedForTransactions	7964000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	199000	usd
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	141644	shares
CY2021	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	534000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11381000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	642000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-37000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94660000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30000000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2080000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8000	usd
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	231324	shares
CY2022	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	468000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12160000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	828000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	45187000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-94660000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1399000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1329000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10843000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	550000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-184000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-413000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1559000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	961000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	426000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1424000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	12160000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11381000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1223000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-236000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	xers	Operating Lease Liabilities Remeasurement Gain Loss OperatingLeaseLiabilitiesRemeasurementGainLoss	1084000	usd
CY2021	xers	Operating Lease Liabilities Remeasurement Gain Loss OperatingLeaseLiabilitiesRemeasurementGainLoss	0	usd
CY2022	xers	Adjustment For Change In Fair Value Of Warrants AdjustmentForChangeInFairValueOfWarrants	1760000	usd
CY2021	xers	Adjustment For Change In Fair Value Of Warrants AdjustmentForChangeInFairValueOfWarrants	-702000	usd
CY2022	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	3157000	usd
CY2021	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13374000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6237000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3887000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3290000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7465000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7418000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4318000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5527000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11384000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12556000	usd
CY2022	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	1777000	usd
CY2021	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	4213000	usd
CY2022	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	7173000	usd
CY2021	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	1110000	usd
CY2022	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	-5280000	usd
CY2021	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-899000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2507000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1187000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-102891000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-95535000	usd
CY2022	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-524000	usd
CY2021	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-1085000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	43020000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	34985000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	103600000	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	38469000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34461000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	97964000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27000000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	54000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	146214000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	43496000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4876000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	737000	usd
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	828000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	642000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	193000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	468000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	534000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	127473000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27247000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59043000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29673000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67271000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37598000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126314000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67271000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	10859000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7294000	usd
CY2022	xers	Issuance Of Warrants For Loan Agreement IssuanceOfWarrantsForLoanAgreement	2080000	usd
CY2021	xers	Issuance Of Warrants For Loan Agreement IssuanceOfWarrantsForLoanAgreement	0	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	137655000	usd
CY2022	xers	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	0	usd
CY2021	xers	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	8871000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	22531000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121966000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67271000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4348000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126314000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67271000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Organization and nature of the business <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of business </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Xeris Biopharma Holdings, Inc. ("Xeris Biopharma" or the "Company") is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing clinically meaningful products across a range of therapies. The Company currently has three commercially available products: Gvoke, a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia; Keveyis, the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis ("PPP"); and Recorlev, approved by the Food and Drug Administration ("FDA") in December 2021, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and XeriJect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 5, 2021, Xeris Pharmaceuticals, Inc. ("Xeris Pharma") acquired Strongbridge Biopharma plc ("Strongbridge"), a biopharmaceutical company commercializing therapies for rare diseases with significant unmet needs. Immediately following the acquisition and related transactions, both Xeris Pharma and Strongbridge became wholly-owned subsidiaries of Xeris Biopharma. The common stock of Xeris Pharma and the ordinary shares of Strongbridge were de-registered after completion of the Transactions (as defined below in Note 4). On October 6, 2021, Xeris Biopharma’s common stock, par value $0.0001 per share, commenced trading on the Nasdaq Global Select Market (“Nasdaq”) under the ticker symbol "XERS". See "Note 4 – Business combination" for a more detailed description of the Transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used herein, the "Company" or "Xeris" refers to Xeris Pharma when referring to periods prior to the acquisition of Strongbridge on October 5, 2021 and to Xeris Biopharma when referring to periods on or subsequent to October 5, 2021. Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, Gvoke Kit and Ogluo (glucagon).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred operating losses since inception and has an accumulated deficit of $554.8 million as of December 31, 2022. The Company expects to continue to incur net losses for at least the next 12 months beyond the issuance date of these consolidated financial statements. Based on the Company’s current operating plans, existing working capital at December 31, 2022, capital raised in 2022, the Company believes that its cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next 12 months from the issuance date of these consolidated financial statements. If needed, the Company may elect to finance its operations through equity or debt financing along with revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that such funding may be available to the Company on acceptable terms, or at all, or that the Company will be able to successfully market and sell Gvoke, Keveyis and Recorlev. Market volatility resulting from COVID-19, geopolitical instability resulting from the ongoing military conflict between Russia and Ukraine, rising interest rates, inflationary pressures, the tightening of lending standards or other factors could also adversely impact the Company's ability to access capital as and when needed. The issuance of equity securities may result in dilution to stockholders. If the Company raises additional funds through the issuance of additional debt, which may have rights, preferences and privileges senior to those of the Company's common stockholders, the terms of the debt could impose significant restrictions on the Company's operations. The failure to raise funds as and when needed could have a negative impact on the Company's financial condition and ability to pursue its business strategies. If additional funding is not secured when required, the Company may need to delay or curtail its operations until such funding is received, which would have a material adverse impact on the business prospects and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Significant risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other specialty pharmaceutical companies, including, but not limited to, successful commercialization and market acceptance of available products and any future products, if and when approved, successful development of the product candidates, the development of new technological innovations by competitors, and protection of intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic has resulted in significant governmental measures being implemented to control the spread of the virus and has caused the Company to modify its business practices (including remote work for most of its employees from time to time). While the Company cannot predict the scope and severity, these developments and measures could materially and adversely affect the business, results of operations and financial condition. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on all aspects of the business and is taking steps to minimize the impact on the business. However, the extent to which COVID-19 impacts the business, results of operations or financial condition will depend on the extent and severity of the continued spread of COVID-19 globally, the effectiveness of actions taken to contain the pandemic or treat its impact, and the resulting economic consequences, among others. Furthermore, if the Company or any of the third parties with whom the Company engages were to experience shutdowns or other business disruptions, the Company's ability to conduct the business in the manner and </span></div>on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on the business, results of operations and financial condition.
CY2022Q4	xers	Number Of Commercially Available Products NumberOfCommerciallyAvailableProducts	3	commerciallyavailableproduct
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-554800000	usd
CY2022	us-gaap	Revenue Performance Obligation Description Of Warranty RevenuePerformanceObligationDescriptionOfWarranty	For some products, the Company's customers generally have the right to return product during the period beginning six months prior to the product expiration date and up to one year after the product expiration date. The Company does not have extensive history of product returns and uses various factors to estimate the provision for returns, including the launch date of products, third-party industry data for comparable products in the market and estimated channel inventory data. In a reporting period, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels, inventory dating, prescription data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products.
CY2022Q4	xers	Revenue Performance Obligation Product Return Rate Increase Decrease Scenario Percent RevenuePerformanceObligationProductReturnRateIncreaseDecreaseScenarioPercent	0.01
CY2022	xers	Revenue Performance Obligation Product Return Impact On Revenue Of1 Increase Decrease RevenuePerformanceObligationProductReturnImpactOnRevenueOf1IncreaseDecrease	1100000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	829000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6883000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1676000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	110248000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49590000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35169000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35162000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7410000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5181000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11367000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7442000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5958000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5495000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24735000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1300000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1000000	usd
CY2021	us-gaap	Interest Expense InterestExpense	7200000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11050000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10762000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5534000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4135000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5516000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	usd
CY2022	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1400000	usd
CY2021	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1300000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11393000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	120607000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	550000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	131450000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10843000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10843000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10843000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10293000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8643000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	69142000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	120607000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1413000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13400000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19638000	usd
CY2022Q4	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	6720000	usd
CY2021Q4	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	6009000	usd
CY2022Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	562000	usd
CY2021Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	595000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2593000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3237000	usd
CY2022Q4	xers	Accruedresearchcosts Accruedresearchcosts	1411000	usd
CY2021Q4	xers	Accruedresearchcosts Accruedresearchcosts	1998000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2799000	usd
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6715000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4656000	usd
CY2022Q4	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	usd
CY2021Q4	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	1839000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4645000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7644000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36786000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	usd
CY2020Q3	xers	Convertible Notes Purchased Due To Exercise Of Underwriter Option ConvertibleNotesPurchasedDueToExerciseOfUnderwriterOption	11300000	usd
	xers	Principal Amount Of Convertible Notes Converted PrincipalAmountOfConvertibleNotesConverted	8400000	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2736591	shares
CY2020Q4	xers	Principal Amount Of Convertible Notes Converted Privately PrincipalAmountOfConvertibleNotesConvertedPrivately	30700000	usd
CY2020Q4	xers	Stock Issued During Period Shares Conversion Of Convertible Securities Privately Exchanged StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPrivatelyExchanged	10435200	shares
CY2020Q4	xers	Loss On The Convertible Note Exchange Transactions LossOnTheConvertibleNoteExchangeTransactions	2600000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	4587000	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2608000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	187075000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	47175000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	150000000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	197175000	usd
CY2022	us-gaap	Interest Expense InterestExpense	15300000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	94012	shares
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	121966000	usd
CY2022Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	25688000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	9000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	67271000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	35162000	usd
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	22531000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1769000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.31
CY2022Q4	xers	Total Common Stock And Preferred Stock Authorized Shares TotalCommonStockAndPreferredStockAuthorizedShares	375000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6553398	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.12
CY2021Q1	xers	Netproceedsfromissuanceofpublicoffering Netproceedsfromissuanceofpublicoffering	26900000	usd
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4714982	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1822000	shares
CY2022	xers	Leastamountofannualincreaseofsharesavailableforissuance Leastamountofannualincreaseofsharesavailableforissuance	386000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9700161	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11362336	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.86
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	175000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.10
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11228	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	87680	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1738267	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.37
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9032882	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.44
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9700161	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.37
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.15
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.90
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.25
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1918000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12160000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11381000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1700000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1
CY2022	xers	Deferred Compensation Accrued Interest Rate DeferredCompensationAccruedInterestRate	0.02
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	1600000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P7Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	10674000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2159000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1799000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1091000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	212000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2678000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1586000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1556000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1820000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1869000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19423000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8441000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10982000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1580000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9402000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10982000	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2400000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1813000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2031000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1981000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1931000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1982000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11741000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	21479000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38734658	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35157496	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20178000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25772000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4325000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4422000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	320000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	350000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	94000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-302000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	726000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1779000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	414000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	901000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1103000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2450000	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	1600000	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	663000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	21162000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29642000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	506000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	311000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1424000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	111631000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	100790000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8836000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7184000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5714000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3177000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32977000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27094000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	159043000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137881000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	115000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	364000	usd
CY2022Q4	xers	Deferred Tax Liabilities Fixedand Intangible Assets DeferredTaxLiabilitiesFixedandIntangibleAssets	11000	usd
CY2021Q4	xers	Deferred Tax Liabilities Fixedand Intangible Assets DeferredTaxLiabilitiesFixedandIntangibleAssets	197000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3622000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5109000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3633000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5306000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3518000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4942000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	501400000	usd
CY2022Q4	xers	Operatinglosscarryforwardsvariousstates Operatinglosscarryforwardsvariousstates	345300000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	475700000	usd
CY2021Q4	xers	Operatinglosscarryforwardsvariousstates Operatinglosscarryforwardsvariousstates	309700000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.80
CY2022Q4	xers	Federalresearchincometaxcreditsgrossofvaluationallowance Federalresearchincometaxcreditsgrossofvaluationallowance	6700000	usd
CY2022Q4	xers	Stateresearchincometaxcreditsgrossofvaluationallowance Stateresearchincometaxcreditsgrossofvaluationallowance	3100000	usd
CY2021Q4	xers	Federalresearchincometaxcreditsgrossofvaluationallowance Federalresearchincometaxcreditsgrossofvaluationallowance	5400000	usd
CY2021Q4	xers	Stateresearchincometaxcreditsgrossofvaluationallowance Stateresearchincometaxcreditsgrossofvaluationallowance	2500000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92493000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	45388000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137881000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21162000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	159043000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	627000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	929000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	92000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	17000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	319000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	722000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	627000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001867096-23-000031-index-headers.html	Edgar Link	pending
0001867096-23-000031-index.html	Edgar Link	pending
0001867096-23-000031.txt	Edgar Link	pending
0001867096-23-000031-xbrl.zip	Edgar Link	pending
a202210-kexhibit231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
a202210-kexhibit311.htm	Edgar Link	pending
a202210-kexhibit312.htm	Edgar Link	pending
a202210-kexhibit321.htm	Edgar Link	pending
a202210-kexhibit322.htm	Edgar Link	pending
a411formoflenderwarranti.htm	Edgar Link	pending
a411formoflenderwarranti001.jpg	Edgar Link	pending
a411formoflenderwarranti002.jpg	Edgar Link	pending
a411formoflenderwarranti003.jpg	Edgar Link	pending
a411formoflenderwarranti004.jpg	Edgar Link	pending
a411formoflenderwarranti005.jpg	Edgar Link	pending
a411formoflenderwarranti006.jpg	Edgar Link	pending
a411formoflenderwarranti007.jpg	Edgar Link	pending
a411formoflenderwarranti008.jpg	Edgar Link	pending
a411formoflenderwarranti009.jpg	Edgar Link	pending
a411formoflenderwarranti010.jpg	Edgar Link	pending
a411formoflenderwarranti011.jpg	Edgar Link	pending
a411formoflenderwarranti012.jpg	Edgar Link	pending
a411formoflenderwarranti013.jpg	Edgar Link	pending
a411formoflenderwarranti014.jpg	Edgar Link	pending
a411formoflenderwarranti015.jpg	Edgar Link	pending
a411formoflenderwarranti016.jpg	Edgar Link	pending
a412formofwarranttocrgro.htm	Edgar Link	pending
a412formofwarranttocrgro001.jpg	Edgar Link	pending
a412formofwarranttocrgro002.jpg	Edgar Link	pending
a412formofwarranttocrgro003.jpg	Edgar Link	pending
a412formofwarranttocrgro004.jpg	Edgar Link	pending
a412formofwarranttocrgro005.jpg	Edgar Link	pending
a412formofwarranttocrgro006.jpg	Edgar Link	pending
a412formofwarranttocrgro007.jpg	Edgar Link	pending
a412formofwarranttocrgro008.jpg	Edgar Link	pending
a412formofwarranttocrgro009.jpg	Edgar Link	pending
a412formofwarranttocrgro010.jpg	Edgar Link	pending
a412formofwarranttocrgro011.jpg	Edgar Link	pending
a412formofwarranttocrgro012.jpg	Edgar Link	pending
a412formofwarranttocrgro013.jpg	Edgar Link	pending
a412formofwarranttocrgro014.jpg	Edgar Link	pending
a412formofwarranttocrgro015.jpg	Edgar Link	pending
a412formofwarranttocrgro016.jpg	Edgar Link	pending
a412formofwarranttocrgro017.jpg	Edgar Link	pending
a412formofwarranttocrgro018.jpg	Edgar Link	pending
a413formofwarranttocrgro.htm	Edgar Link	pending
a413formofwarranttocrgro001.jpg	Edgar Link	pending
a413formofwarranttocrgro002.jpg	Edgar Link	pending
a413formofwarranttocrgro003.jpg	Edgar Link	pending
a413formofwarranttocrgro004.jpg	Edgar Link	pending
a413formofwarranttocrgro005.jpg	Edgar Link	pending
a413formofwarranttocrgro006.jpg	Edgar Link	pending
a413formofwarranttocrgro007.jpg	Edgar Link	pending
a413formofwarranttocrgro008.jpg	Edgar Link	pending
a413formofwarranttocrgro009.jpg	Edgar Link	pending
a413formofwarranttocrgro010.jpg	Edgar Link	pending
a413formofwarranttocrgro011.jpg	Edgar Link	pending
a414formofwarranttoavenu.htm	Edgar Link	pending
a414formofwarranttoavenu001.jpg	Edgar Link	pending
a414formofwarranttoavenu002.jpg	Edgar Link	pending
a414formofwarranttoavenu003.jpg	Edgar Link	pending
a414formofwarranttoavenu004.jpg	Edgar Link	pending
a414formofwarranttoavenu005.jpg	Edgar Link	pending
a414formofwarranttoavenu006.jpg	Edgar Link	pending
a414formofwarranttoavenu007.jpg	Edgar Link	pending
a414formofwarranttoavenu008.jpg	Edgar Link	pending
a414formofwarranttoavenu009.jpg	Edgar Link	pending
a414formofwarranttoavenu010.jpg	Edgar Link	pending
a414formofwarranttoavenu011.jpg	Edgar Link	pending
a414formofwarranttoavenu012.jpg	Edgar Link	pending
a414formofwarranttoavenu013.jpg	Edgar Link	pending
a414formofwarranttoavenu014.jpg	Edgar Link	pending
a414formofwarranttoavenu015.jpg	Edgar Link	pending
a414formofwarranttoavenu016.jpg	Edgar Link	pending
a414formofwarranttoavenu017.jpg	Edgar Link	pending
a414formofwarranttoavenu018.jpg	Edgar Link	pending
a414formofwarranttoavenu019.jpg	Edgar Link	pending
a414formofwarranttoavenu020.jpg	Edgar Link	pending
a414formofwarranttoavenu021.jpg	Edgar Link	pending
a414formofwarranttoavenu022.jpg	Edgar Link	pending
a414formofwarranttoavenu023.jpg	Edgar Link	pending
a414formofwarranttoavenu024.jpg	Edgar Link	pending
a414formofwarranttoavenu025.jpg	Edgar Link	pending
a414formofwarranttoavenu026.jpg	Edgar Link	pending
a414formofwarranttoavenu027.jpg	Edgar Link	pending
a414formofwarranttoavenu028.jpg	Edgar Link	pending
a414formofwarranttoavenu029.jpg	Edgar Link	pending
a414formofwarranttoavenu030.jpg	Edgar Link	pending
a414formofwarranttoavenu031.jpg	Edgar Link	pending
a414formofwarranttoavenu032.jpg	Edgar Link	pending
a414formofwarranttoavenu033.jpg	Edgar Link	pending
a414formofwarranttoavenu034.jpg	Edgar Link	pending
a414formofwarranttoavenu035.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeris-ex211xlistofsubsidia.htm	Edgar Link	pending
xers-20221231.htm	Edgar Link	pending
xers-20221231.xsd	Edgar Link	pending
xers-20221231_g1.jpg	Edgar Link	pending
xers-20221231_cal.xml	Edgar Link	unprocessable
xers-20221231_def.xml	Edgar Link	unprocessable
xers-20221231_pre.xml	Edgar Link	unprocessable
xers-20221231_lab.xml	Edgar Link	unprocessable
xers-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

2023 Q1 Form 10-K Financial Statement

#000186709623000031 Filed on March 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS Xeris Biopharma Holdings, Inc. Stock $xers

2023 Q1 Form 10-K Financial Statement

#000186709623000031 Filed on March 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers